Here's a study on benfotiamine in a mouse model of Alzheimer's -
Benfotiamine treatment activates the Nrf2/ARE pathway and is neuroprotective in a transgenic mouse model of tauopathyncbi.nlm.nih.gov/pmc/articl...
Abstract
"Impaired glucose metabolism, decreased levels of thiamine and its
phosphate esters, and reduced activity of thiamine-dependent enzymes,
such as pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase and
transketolase occur in Alzheimer’s disease (AD). Thiamine deficiency
exacerbates amyloid beta (Aβ) deposition, tau hyperphosphorylation and
oxidative stress. Benfotiamine (BFT) rescued cognitive deficits and
reduced Aβ burden in amyloid precursor protein (APP)/PS1 mice. In this
study, we examined whether BFT confers neuroprotection against tau
phosphorylation and the generation of neurofibrillary tangles (NFTs) in
the P301S mouse model of tauopathy. Chronic dietary treatment with BFT
increased lifespan, improved behavior, reduced glycated tau, decreased
NFTs and prevented death of motor neurons. BFT administration
significantly ameliorated mitochondrial dysfunction and attenuated
oxidative damage and inflammation. We found that BFT and its metabolites
(but not thiamine) trigger the expression of Nrf2/antioxidant response
element (ARE)-dependent genes in mouse brain as well as in wild-type but
not Nrf2-deficient fibroblasts. Active metabolites were more potent in
activating the Nrf2 target genes than the parent molecule BFT. Docking
studies showed that BFT and its metabolites (but not thiamine) bind to
Keap1 with high affinity. These findings demonstrate that BFT activates
the Nrf2/ARE pathway and is a promising therapeutic agent for the
treatment of diseases with tau pathology, such as AD, frontotemporal
dementia and progressive supranuclear palsy."
Excerpt from Discussion
"After oral administration, BFT is hydrolyzed in the intestine into the
lipophilic s-BT that diffuses across the epithelial membranes into the
blood or liver, where it is converted into thiamine (40).
As a result, blood thiamine concentrations reach 5-fold higher levels
and persist longer than after administration of an equivalent dose of
thiamine. Nevertheless, the magnitude of the rate of thiamine uptake
into the brain is limited, in part, by a self-exchange mechanism
catalyzed by the high affinity thiamine transporter (2)."